May 4, 2026 - ROIS, the global contract development and manufacturing organization (CDMO) formerly operating as ROVI Pharma Industrial Services, announced the completion of its acquisition of a commercial injectable drug manufacturing facility in Phoenix, Arizona from Bristol Myers Squibb (BMS). The deal includes a five-year manufacturing agreement valued at approximately $250 million.
The Phoenix facility spans approximately 34,000 square meters and is equipped for sterile injectable drug product manufacturing, automated inspection, device assembly, labeling, and final packaging. The acquisition positions ROIS as a transatlantic CDMO with direct U.S. production capacity.
The Phoenix facility brings specialized capabilities in antibody-drug conjugate (ADC) manufacturing and cytotoxic drug production, including specialized containment and conjugation capabilities, cytotoxic lyophilization, and commercial-scale aseptic filling for injectable products.
The divestiture reflects BMS portfolio optimization strategy. BMS will continue producing products at the Phoenix facility under the five-year agreement. For ROIS, the deal provides immediate access to an established U.S. manufacturing footprint and regulatory track record.
The deal is part of a broader wave of CDMO consolidation driven by U.S. reshoring pressure, ADC pipeline growth with over 100 candidates in clinical trials, and intensifying global competition from Chinese and Korean CDMOs.
The expansion of ADC and cytotoxic manufacturing creates supply chain opportunities in high-potency API supply, linker intermediates, sterile excipients, and packaging components.
The ROIS-BMS deal exemplifies a maturing CDMO market where scale, specialization, and geographic reach determine competitive positioning. For pharmaceutical suppliers, aligning with CDMOs that have ADC capabilities will be essential for capturing biologics manufacturing growth.
